Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the outbreak of coronavirus disease 2019 in Wuhan City, China. The SARS-CoV-2 is genetically similar to the coronavirus derived from bat. The SARS-CoV-2, the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to beta coronavirus. Since the outbreak of the coronavirus disease 2019, effective antiviral drugs have become a hot issue in the world. Very little about SARS-CoV-2 is known and there is no precedent for treatment. The National Health Commission has repeatedly revised the diagnosis and treatment guide for the coronavirus disease 2019. The latest guide is "New Coronary Virus-Infected Pneumonia Diagnosis and Treatment Plan (Seventh Trial Version)"(short for Seventh Version of Diagnosis and Treatment Plan). But the use of antiviral drugs is still on trial and no rigorous clinical trials data is available. Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir. But the later 2 drugs aren't mentioned in the Seventh Version of Diagnosis and Treatment Plan.
严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2，SARS-CoV-2)是导致武汉2019冠状病毒病暴发流行的致病原。SARS-CoV-2与一种蝙蝠来源的新型冠状病毒在遗传学上比较接近，与SARS-CoV和中东呼吸综合征冠状病毒(Middle East respiratory syndrome coronavirus，MERS-CoV)同为β属冠状病毒。自从2019冠状病毒病疫情暴发以来，有效的抗病毒药物成为业界和大众关注的热点问题。然而，目前抗病毒药物的使用仍为试用，尚没有严谨的临床试验数据支撑。热门的抗SARS-CoV-2药物为第七版诊疗方案中提到的α-干扰素、利巴韦林、洛匹那韦/利托那韦、磷酸氯喹、阿比多尔，以及该方案中未提及的硫酸羟氯喹和瑞德西韦。.
Keywords: antiviral drugs; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2.